140651-18-9
140651-18-9
Chemical Structure
CAN508
- CAS No.: 140651-18-9
- Formula:C9H10N6O
- Molecular Weight:218.22
IUPAC Name: (E)-4-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
InChIKey: AYZRKFOEZQBUEA-OUKQBFOZSA-N
SMILES: OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1
Biological Activity: CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CAN508 | 99.71% | CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509. [Content Brief]
- [2]. Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710. [Content Brief]
